Paper Details

  1. Home
  2. Paper Details

Observational retrospective study of vascular modulator changes during treatment in essential thrombocythemia.

Author: CorvettaDaisy, Di PierroAngela Maria, EakinsElva, FeistritzerClemens, GambatoRoberto, GastlGünther, GherlinzoniFilippo, GottardiMichele, KramperaMauro, LangesMartin, MarcheselliLuigi, MazzoleniGuido, MegaAndrea, MurphyCiaran, PacquolaEnrica, PerbelliniOmar, PiccinAndrea, PivaElisa, PlebaniMario, PuscedduIrene, SteurerMichael, TauberMartina, Van SchilfgaardeMuriel, VeneriDino

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Essential thrombocythemia (ET) is a blood disorder that increases the risk of blood clots. This study investigated the effects of hydroxyurea (HU) and anagrelide (ANA), two common treatments for ET, on microparticle generation and endothelial activity. The study found that both HU and ANA reduced platelet count, but affected endothelial modulators differently. HU increased nitric oxide (NO) and adrenomedullin (ADM) levels, promoting vasodilation, while ANA reduced endothelin-1 (ET-1) levels, impairing vasoconstriction.
Paper Details　
Original Abstract of the Article :
Essential thrombocythemia (ET) patients are at risk of developing thrombotic events. Qualitative platelet (PLT) abnormalities and activation of endothelial cells (ECs) and PLTs are thought to be involved. Microparticles (MPs) can originate from PLTs (PMPs), ECs (EMPs), or red cells (RMPs). Previous ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.trsl.2017.02.001

データ提供：米国国立医学図書館（NLM）

Understanding Vascular Modulator Changes in Essential Thrombocythemia Treatment

Essential thrombocythemia (ET) is a blood disorder characterized by an overproduction of platelets, increasing the risk of thrombotic events. This study investigates the impact of various treatments for ET on vascular modulators, including nitric oxide (NO), adrenomedullin (ADM), and endothelin-1 (ET-1), as well as microparticle (MP) generation. The researchers analyzed data from 63 patients with ET, comparing those treated with hydroxyurea (HU), anagrelide (ANA), aspirin (ASA), and untreated patients.

Treatment Effects on Vascular Modulators and Microparticles

The study found that both HU and ANA, common treatments for ET, had significant effects on vascular modulators and MP generation. HU increased NO and ADM levels, promoting vasodilation, while ANA decreased ET-1 levels, reducing vasoconstriction. These effects were accompanied by changes in MP production, with HU increasing prothrombotic MPs and ANA reducing their levels.

Navigating Essential Thrombocythemia Treatment: A Multifaceted Approach

This study highlights the complex interplay between ET treatments, vascular modulators, and MP generation. It suggests that HU and ANA, while acting through different mechanisms, can have similar final effects on vascular function. This emphasizes the importance of considering a multifaceted approach to ET treatment, addressing not only platelet count but also vascular health and thrombotic risk.

Dr. Camel's Conclusion

This research provides a deeper understanding of the intricate mechanisms involved in ET treatment. Like a camel who adapts to the desert's ever-changing environment, healthcare professionals must understand how ET treatments impact various aspects of vascular function. This study encourages a holistic approach to ET management, considering the interconnectedness of vascular modulators, microparticles, and platelet count to ensure optimal patient outcomes.

Date :
  1. Date Completed 2017-09-11
  2. Date Revised 2018-03-14
Further Info :

Pubmed ID

28259616

DOI: Digital Object Identifier

10.1016/j.trsl.2017.02.001

Related Literature

Article Analysis
・Effects of anagrelide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.